{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-07-17T09:21:06.486354+00:00","company":{"ticker":"PALX","cik":1938569,"company_name":"Palomino Laboratories Inc."},"pagination":{"limit":100,"returned":10,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"ma_counterparty":[{"display_name":"Private Palomino","detail":"change_of_control","count":1,"first_seen":"2025-10-06T23:59:59+00:00","last_seen":"2025-10-06T23:59:59+00:00","evidence_fact_ids":[26809]}]},"facts":[{"fact_type":"equity_issuance","fact_key":"4e0f4a9b74a49fd95d9be665563e145171574db0","cik":1938569,"ticker":"PALX","company_name":"Palomino Laboratories Inc.","filed_at":"2026-05-05T23:59:59+00:00","payload":{"action":"warrant_issuance","consideration_text":"services as placement agent","effective_date":"2026-04-30","item_codes_triggered":["3.02"],"purchaser":"Laidlaw & Company (UK) Ltd.","security_type":"warrant","shares_text":"374,761 warrants"},"claim":"Palomino Laboratories Inc. issued 374,761 warrants of warrant to Laidlaw & Company (UK) Ltd. for services as placement agent.","evidence_excerpt":"The Placement Agent also received 374,761 warrants to purchase shares of Common Stock which are exercisable for five (5) years and have an exercise price equal to 120% of the lowest price per share of the shares of Common Stock issued or issuable to investors in the Offering (the “ Placement Agent Warrants ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-021282","anchor_url":"https://secwatch.observer/filing/0001493152-26-021282#claim-4e0f4a9b74a49fd95d9be665563e145171574db0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1938569/000149315226021282/0001493152-26-021282-index.htm"},{"fact_type":"equity_issuance","fact_key":"644ff608a6be495afccd5e15399e5bd46bd858f1","cik":1938569,"ticker":"PALX","company_name":"Palomino Laboratories Inc.","filed_at":"2026-05-05T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"gross proceeds of $1,880,000.00","effective_date":"2026-04-30","item_codes_triggered":["3.02"],"purchaser":"certain accredited investors","security_type":"common_stock","shares_text":"470,000 Shares"},"claim":"Palomino Laboratories Inc. issued 470,000 Shares of common stock to certain accredited investors for gross proceeds of $1,880,000.00.","evidence_excerpt":"On April 30, 2026, the Company and certain accredited investors mutually agreed to effect, and effected, an additional closing, with respect to 470,000 Shares for gross proceeds of $1,880,000.00 (the “ Second Closing ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-021282","anchor_url":"https://secwatch.observer/filing/0001493152-26-021282#claim-644ff608a6be495afccd5e15399e5bd46bd858f1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1938569/000149315226021282/0001493152-26-021282-index.htm"},{"fact_type":"equity_issuance","fact_key":"cd25e888936e2bfc030c9b9b9beee64fae5e9cac","cik":1938569,"ticker":"PALX","company_name":"Palomino Laboratories Inc.","filed_at":"2026-04-24T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"$4.00 per Share","effective_date":"2026-04-20","item_codes_triggered":["3.02"],"purchaser":"certain accredited investors","security_type":"common_stock","shares_text":"3,773,853 shares"},"claim":"Palomino Laboratories Inc. issued 3,773,853 shares of common stock to certain accredited investors for $4.00 per Share.","evidence_excerpt":"On April 20, 2026, Palomino Laboratories Inc. (the “ Company ”) entered into subscription agreements (each a “ Subscription Agreement ”) with certain accredited investors and sold in an initial closing (the “ Initial Closing ”) of a private placement (the “ Offering ”) an aggregate of 3,773,853 shares (the “ Shares ”) of the Company’s common stock, par value $0.0001 per share (the “ Common Stock ”), for an aggregate purchase price of $15,095,412.00, at a purchase price of $4.00 per Share.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-26-018963","anchor_url":"https://secwatch.observer/filing/0001493152-26-018963#claim-cd25e888936e2bfc030c9b9b9beee64fae5e9cac","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1938569/000149315226018963/0001493152-26-018963-index.htm"},{"fact_type":"equity_issuance","fact_key":"2177a00a5f7e6022c4aee1f51e357414aa9a6c8c","cik":1938569,"ticker":"PALX","company_name":"Palomino Laboratories Inc.","filed_at":"2025-10-30T23:59:59+00:00","payload":{"action":"warrant_issuance","consideration_text":null,"effective_date":"2025-10-24","item_codes_triggered":["3.02"],"purchaser":"Laidlaw & Company (UK) Ltd. (the “Placement Agent”)","security_type":"warrant","shares_text":"18,333 warrants"},"claim":"Palomino Laboratories Inc. issued 18,333 warrants of warrant to Laidlaw & Company (UK) Ltd. (the “Placement Agent”).","evidence_excerpt":"Laidlaw & Company (UK) Ltd. (the “Placement Agent”) was paid at closing (a) a cash commission of 10.0% of the aggregate gross purchase price (b) a non-allocable expense allowance equal to 2.0% of the aggregate gross purchase price, and (c) received 18,333 warrants (the “Placement Agent Warrants”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-25-020229","anchor_url":"https://secwatch.observer/filing/0001493152-25-020229#claim-2177a00a5f7e6022c4aee1f51e357414aa9a6c8c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1938569/000149315225020229/0001493152-25-020229-index.htm"},{"fact_type":"equity_issuance","fact_key":"b91f50046a421a6609d63ae471bd5ebd00ebfb04","cik":1938569,"ticker":"PALX","company_name":"Palomino Laboratories Inc.","filed_at":"2025-10-30T23:59:59+00:00","payload":{"action":"private_placement","consideration_text":"gross proceeds of $275,001.00, $1.50 per Unit","effective_date":"2025-10-24","item_codes_triggered":["3.02"],"purchaser":"accredited investors","security_type":"unit","shares_text":"183,334 Units"},"claim":"Palomino Laboratories Inc. issued 183,334 Units of unit to accredited investors for gross proceeds of $275,001.00, $1.50 per Unit.","evidence_excerpt":"On October 24, 2025, the Company and certain accredited investors mutually agreed to effect, and effected, an additional closing, with respect to 183,334 Units for gross proceeds of $275,001.00 (the “Offering”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-25-020229","anchor_url":"https://secwatch.observer/filing/0001493152-25-020229#claim-b91f50046a421a6609d63ae471bd5ebd00ebfb04","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1938569/000149315225020229/0001493152-25-020229-index.htm"},{"fact_type":"governance_change","fact_key":"c70965e93f610a7a370ee77dc0059d9dca6cfe53","cik":1938569,"ticker":"PALX","company_name":"Palomino Laboratories Inc.","filed_at":"2025-10-06T23:59:59+00:00","payload":{"change_type":"shell_status","effective_date":null,"item_codes_triggered":["5.06"],"summary_text":"Ceased to be a shell company as a result of the merger."},"claim":"Palomino Laboratories Inc.: Ceased to be a shell company as a result of the merger.","evidence_excerpt":"Prior to the Merger, we were a “shell company” (as such term is defined in Rule 12b-2 under the Exchange Act). As a result of the Merger, the Company has ceased to be a shell company.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-25-016939","anchor_url":"https://secwatch.observer/filing/0001493152-25-016939#claim-c70965e93f610a7a370ee77dc0059d9dca6cfe53","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1938569/000149315225016939/0001493152-25-016939-index.htm"},{"fact_type":"governance_change","fact_key":"d450ed5c2e682c1243706b3c5d10d443f7beeb04","cik":1938569,"ticker":"PALX","company_name":"Palomino Laboratories Inc.","filed_at":"2025-10-06T23:59:59+00:00","payload":{"change_type":"code_of_ethics","effective_date":null,"item_codes_triggered":["5.05"],"summary_text":"Adopted a new Code of Ethics applicable to directors, officers, and employees in connection with the merger."},"claim":"Palomino Laboratories Inc.: Adopted a new Code of Ethics applicable to directors, officers, and employees in connection with the merger.","evidence_excerpt":"In connection with the Merger, the board of directors adopted a new Code of Ethics, which applies to all directors, officers (including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions) and employees.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-25-016939","anchor_url":"https://secwatch.observer/filing/0001493152-25-016939#claim-d450ed5c2e682c1243706b3c5d10d443f7beeb04","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1938569/000149315225016939/0001493152-25-016939-index.htm"},{"fact_type":"governance_change","fact_key":"7e3c16bfafca511bb5a878cedf59babbc0c7cc7e","cik":1938569,"ticker":"PALX","company_name":"Palomino Laboratories Inc.","filed_at":"2025-10-06T23:59:59+00:00","payload":{"change_type":"bylaw_amendment","effective_date":null,"item_codes_triggered":["5.03"],"summary_text":"Amended and restated bylaws in their entirety, effective upon closing of the merger."},"claim":"Palomino Laboratories Inc.: Amended and restated bylaws in their entirety, effective upon closing of the merger.","evidence_excerpt":"Prior to the Merger, we amended and restated our bylaws in their entirety, to be effective upon closing of the Merger.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-25-016939","anchor_url":"https://secwatch.observer/filing/0001493152-25-016939#claim-7e3c16bfafca511bb5a878cedf59babbc0c7cc7e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1938569/000149315225016939/0001493152-25-016939-index.htm"},{"fact_type":"governance_change","fact_key":"f1e0a8928acd3217ac8b690d96da4fea9c980005","cik":1938569,"ticker":"PALX","company_name":"Palomino Laboratories Inc.","filed_at":"2025-10-06T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-09-28","item_codes_triggered":["5.03"],"summary_text":"Amended and restated certificate of incorporation approved by board and stockholders on September 28, 2025, effective upon merger closing."},"claim":"Palomino Laboratories Inc.: Amended and restated certificate of incorporation approved by board and stockholders on September 28, 2025, effective upon merger closing (effective 2025-09-28).","evidence_excerpt":"Prior to the Merger, Unite Acquisition’s board of directors approved the amendment and restatement of our certificate of incorporation on September 28, 2025, and stockholders holding 100% of the then outstanding shares of our Common Stock approved the amendment and restatement to our certificate of incorporation on September 28, 2025.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-25-016939","anchor_url":"https://secwatch.observer/filing/0001493152-25-016939#claim-f1e0a8928acd3217ac8b690d96da4fea9c980005","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1938569/000149315225016939/0001493152-25-016939-index.htm"},{"fact_type":"ma_transaction","fact_key":"2beec33489939a2f24675d67da61c6a4deb26b09","cik":1938569,"ticker":"PALX","company_name":"Palomino Laboratories Inc.","filed_at":"2025-10-06T23:59:59+00:00","payload":{"action":"change_of_control","closing_date":"2025-09-29","consideration_text":null,"counterparty":"Private Palomino","effective_date":"2025-09-29","item_codes_triggered":["2.01","5.01"]},"claim":"Palomino Laboratories Inc. underwent a change of control involving Private Palomino (closed 2025-09-29).","evidence_excerpt":"On September 29, 2025, Unite Acquisition’s wholly owned subsidiary, Palomino Acquisition Co., a Delaware corporation formed in the State of Delaware on August 19, 2025 (“ Merger Sub ”), merged with and into Palomino Laboratories Inc., a privately held Delaware corporation (prior to the Merger, “ Private Palomino ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001493152-25-016939","anchor_url":"https://secwatch.observer/filing/0001493152-25-016939#claim-2beec33489939a2f24675d67da61c6a4deb26b09","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1938569/000149315225016939/0001493152-25-016939-index.htm"}]}